SCHEMBL7186674

SCHEMBL7186674

CCOc1ccc(PC(=O)c2c(Cl)cccc2OC)cc1.[LiH]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
MAPT P10636 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
TP53 P04637 2/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
HPGD P15428 1/20 0.42
DPP4 P27487 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183274 0.92 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1MAPTNPC1RAB9A
SCHEMBL7190132 0.92 TAS1R3 (0.44) SMN1; SMN2ALDH1A1TAS1R3TAS1R1MAPT
SCHEMBL7181016 0.90 L3MBTL1 (0.45) SMN1; SMN2MAPTL3MBTL1DPP4KDM4E
SCHEMBL7180811 0.90 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1MAPTNPC1RAB9A
SCHEMBL7189878 0.90 L3MBTL1 (0.46) SMN1; SMN2ALDH1A1TAS1R3TAS1R1MAPT
SCHEMBL7183023 0.88 CA12 (0.44) SMN1; SMN2ALDH1A1MAPTNPC1RAB9A
SCHEMBL7182674 0.88 MAPT (0.46) SMN1; SMN2MAPTTP53L3MBTL1MEN1
SCHEMBL7179710 0.88 L3MBTL1 (0.43) SMN1; SMN2ALDH1A1MAPTL3MBTL1HPGD
SCHEMBL7189280 0.87 MAPT (0.45) MAPTTP53L3MBTL1TDP1
SCHEMBL7190315 0.87 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1MAPTL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885ALDH1A1 3416/4885TAS1R3 2990/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885ALDH1A1 3984/4885TAS1R3 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.